U.S. Markets closed
  • S&P Futures

    3,856.25
    +11.25 (+0.29%)
     
  • Dow Futures

    31,151.00
    +55.00 (+0.18%)
     
  • Nasdaq Futures

    13,368.75
    +74.50 (+0.56%)
     
  • Russell 2000 Futures

    2,159.10
    +1.40 (+0.06%)
     
  • Crude Oil

    53.28
    +0.04 (+0.08%)
     
  • Gold

    1,870.20
    +3.70 (+0.20%)
     
  • Silver

    25.98
    +0.21 (+0.81%)
     
  • EUR/USD

    1.2136
    +0.0021 (+0.1699%)
     
  • 10-Yr Bond

    1.0900
    -0.0020 (-0.18%)
     
  • Vix

    21.58
    -1.66 (-7.14%)
     
  • GBP/USD

    1.3685
    +0.0029 (+0.2148%)
     
  • USD/JPY

    103.5240
    -0.0460 (-0.0444%)
     
  • BTC-USD

    34,535.25
    -127.36 (-0.37%)
     
  • CMC Crypto 200

    685.63
    -14.98 (-2.14%)
     
  • FTSE 100

    6,740.39
    +27.44 (+0.41%)
     
  • Nikkei 225

    28,727.48
    +204.22 (+0.72%)
     

Top Ranked Momentum Stocks to Buy for April 20th

Zacks Equity Research
·3 min read

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 20th:

Aravive, Inc. (ARAV): This clinical stage biotechnology company has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 18.6% over the last 60 days. 

ARAVIVE, INC Price and Consensus

ARAVIVE, INC Price and Consensus
ARAVIVE, INC Price and Consensus

ARAVIVE, INC price-consensus-chart | ARAVIVE, INC Quote

Aravive’s shares gained more than 100% over the last one month above the S&P 500’s increase of 19.3%. The company possesses a Momentum Score of B.

ARAVIVE, INC Price

ARAVIVE, INC Price
ARAVIVE, INC Price

ARAVIVE, INC price | ARAVIVE, INC Quote

Celyad SA (CYAD): This clinical-stage biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 14.9% over the last 60 days.

Celyad SA Price and Consensus

Celyad SA Price and Consensus
Celyad SA Price and Consensus

Celyad SA price-consensus-chart | Celyad SA Quote

Celyad’s shares gained 84.3% over the last one month. The company possesses a Momentum Score of B.

Celyad SA Price

Celyad SA Price
Celyad SA Price

Celyad SA price | Celyad SA Quote

Mersana Therapeutics, Inc. (MRSN): This clinical stage biopharmaceutical company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 2.6% over the last 60 days.

Mersana Therapeutics, Inc. Price and Consensus

Mersana Therapeutics, Inc. Price and Consensus
Mersana Therapeutics, Inc. Price and Consensus

Mersana Therapeutics, Inc. price-consensus-chart | Mersana Therapeutics, Inc. Quote

Mersana Therapeutics’ shares gained 78.5% over the last one month. The company possesses a Momentum Score of B.

Mersana Therapeutics, Inc. Price

Mersana Therapeutics, Inc. Price
Mersana Therapeutics, Inc. Price

Mersana Therapeutics, Inc. price | Mersana Therapeutics, Inc. Quote

BioCryst Pharmaceuticals, Inc. (BCRX): This biotechnology company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 9.3% over the last 60 days.

BioCryst Pharmaceuticals, Inc. Price and Consensus

BioCryst Pharmaceuticals, Inc. Price and Consensus
BioCryst Pharmaceuticals, Inc. Price and Consensus

BioCryst Pharmaceuticals, Inc. price-consensus-chart | BioCryst Pharmaceuticals, Inc. Quote

BioCryst Pharmaceuticals’ shares gained 32.1% over the last one month. The company possesses a Momentum Score of B.

BioCryst Pharmaceuticals, Inc. Price

BioCryst Pharmaceuticals, Inc. Price
BioCryst Pharmaceuticals, Inc. Price

BioCryst Pharmaceuticals, Inc. price | BioCryst Pharmaceuticals, Inc. Quote

See the full list of top ranked stocks here

Learn more about the Momentum score and how it is calculated here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>                                     


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Mersana Therapeutics, Inc. (MRSN) : Free Stock Analysis Report
 
Celyad SA (CYAD) : Free Stock Analysis Report
 
BioCryst Pharmaceuticals, Inc. (BCRX) : Free Stock Analysis Report
 
ARAVIVE, INC (ARAV) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research